Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database.
Enoch ChangSarah S MougalianKerin B AdelsonMelissa R YoungJames B YuPublished in: Breast cancer research and treatment (2018)
Prolonged MFI greater than 10 years between initial breast cancer diagnosis and subsequent metastatic disease was found to be associated with improved recurrent MBC 5-year survival and decreased risk of breast cancer-specific mortality. This has potential implications for counseling patients as to prognosis, choice of treatment, as well as the stratification of patients considered for MBC clinical trials.
Keyphrases
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- squamous cell carcinoma
- small cell lung cancer
- chronic kidney disease
- peritoneal dialysis
- metastatic breast cancer
- prognostic factors
- emergency department
- cardiovascular disease
- coronary artery disease
- cardiovascular events
- risk assessment
- smoking cessation